MolDX: Breast Cancer Index® (BCI) Gene Expression Test

The Breast Cancer Index (BCI) test is covered only for postmenopausal women with invasive, ER+ and/or PR+, HER2- early-stage breast cancer (TNM T1-T3, pN0-pN1, M0) with no distant metastasis. Coverage requires that test results will be used to inform decisions about adding chemotherapy and/or extending endocrine therapy to estimate distant recurrence risk and endocrine responsiveness. Coverage is excluded for premenopausal women, males, tumors not meeting receptor/HER2 criteria, metastatic or relapsed disease, and situations where results will not guide treatment decisions.

"Covered for postmenopausal women with invasive carcinoma of the breast."

Sign up to see full coverage criteria, indications, and limitations.